Oxford, UK, 28 April 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'
Ridinilazole is a novel class antibiotic with potential for broad use in the treatment of CDI. In a Phase 2 clinical trial, ridinilazole showed statistical superiority over vancomycin in rates of sustained clinical response, an endpoint that captures both initial cure and recurrence of CDI.